Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma

Kara M. Kelly, David Hodgson, Burton Appel, Lu Chen, Peter D. Cole, Terzah Horton, Frank G. Keller

Research output: Contribution to journalReview article

34 Scopus citations

Abstract

In childhood Hodgkin lymphoma, estimated 5 years survival rates exceed 90%. Long-term survival continues to decline from delayed toxicities. Key findings from recent Children's Oncology Group trials include: (1) Radiotherapy selection may be based on early chemotherapy response assessed by both FDG-PET and CT imaging, (2) A new prognostic factor score stratifies patients into risk categories; and (3) novel retrieval regimens were identified. A phase I/II trial is investigating Brentuximab vedotin (Bv) with gemcitabine in relapsed patients. A phase 3 trial will modify conventional chemotherapy and radiotherapy approaches through the addition of Bv, while incorporating translational biology to identify molecular targets.

Original languageEnglish (US)
Pages (from-to)972-978
Number of pages7
JournalPediatric Blood and Cancer
Volume60
Issue number6
DOIs
StatePublished - Jun 1 2013

Keywords

  • Biomarkers
  • Children
  • Clinical trials
  • Hodgkin lymphoma
  • Malignancies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Kelly, K. M., Hodgson, D., Appel, B., Chen, L., Cole, P. D., Horton, T., & Keller, F. G. (2013). Children's Oncology Group's 2013 blueprint for research: Hodgkin lymphoma. Pediatric Blood and Cancer, 60(6), 972-978. https://doi.org/10.1002/pbc.24423